Semantic Scholar uses AI to extract papers important to this topic.
In the last few years, the therapeutic approach for neuroendocrine neoplasms (NENs) has changed dramatically following the… Expand AbstractBackgroundMetastatic colorectal cancer (mCRC) patients with progressive disease after all available standard therapies… Expand ABSTRACT Introduction: Anti-angiogenetic agents are currently the standard of care in metastatic CRC patients. Bevacizumab… Expand 513 Background: Colorectal cancer (CRC) is the third most frequently diagnosed cancer and is the fifth leading cause of cancer… Expand The 2015 Gastrointestinal Cancers Symposium (San Francisco, CA, USA; January 15–17) is the world-class conference co-sponsored by… Expand Purpose: Famitinib is a novel tyrosine kinase inhibitor. We investigated the effects of famitinib on the radiosensitivity of… Expand AbstractPurpose
Hypothyroidism is a common adverse event in patients treated with anti-VEGFR-2 targeting agents and may be a… Expand Famitinib is a novel multi‐targeted receptor tyrosine kinase inhibitor under development for cancer treatment. This study aims to… Expand AbstractPurpose
To evaluate the safety, tolerability, pharmacokinetics and antitumor activities of famitinib (famitinib l-malate… Expand Background Famitinib is a novel and potent multitargeting receptor tyrosine kinase inhibitor. The phase I clinical study showed… Expand